What is the recommended dose and duration of clomiphene citrate for a man with infertility?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 7, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Clomiphene Citrate Dosing for Male Infertility

For men with idiopathic infertility and normal testosterone levels, clomiphene citrate 25 mg daily for 25 days followed by 5 days rest, repeated for 3-4 months, is the recommended regimen, though the benefits are small and likely outweighed by assisted reproductive technologies like IVF. 1

Evidence-Based Dosing Recommendations

Standard Dosing Protocol

  • 25 mg daily for 25 days, followed by 5-day rest period, repeated for 3-4 months is the most commonly studied and effective regimen 2, 3, 4
  • An alternate-day regimen (25 mg every other day) may yield superior results in sperm concentration and total sperm count compared to daily dosing, with pregnancy rates of 26.7% versus 20.5% 5
  • Higher doses (50 mg daily) have been studied but the 25 mg dose appears optimal for balancing efficacy with safety 6

Treatment Duration

  • Minimum 3 months of therapy is required to observe meaningful improvements in spermatogenesis, as this reflects the approximate duration of the spermatogenic cycle 2, 3, 4
  • Reassess semen parameters at 3 months and again 6-8 weeks after completing therapy 3

Patient Selection Criteria

Appropriate Candidates

  • Men with normogonadotropic oligozoospermia (FSH 2-10 mIU/mL, normal or low-normal LH and testosterone) 6, 3
  • Normal or low-normal prolactin and estradiol levels at baseline 3
  • No end-organ pathology of the testes 2

Contraindications

  • Avoid in patients with liver disease, especially decompensated cirrhosis, due to potential hepatotoxicity 7
  • Not indicated for men with hypogonadotropic hypogonadism (hCG is preferred) 8

Expected Outcomes and Limitations

Efficacy Data

  • Sperm count improvements: In extreme oligozoospermia (mean 3.84 million/mL), count increased to 8.2 million/mL; in moderate oligozoospermia (mean 13.05 million/mL), count increased to 24.55 million/mL 2
  • Motile sperm count also improves significantly 2, 5
  • Pregnancy rates range from 13-27% after 6 months of follow-up 3, 5

Critical Limitations

The AUA/ASRM guidelines explicitly state that benefits of clomiphene in idiopathic male infertility are small and outweighed by the distinct advantages of medically-assisted reproduction (IVF), which offers higher pregnancy rates and earlier conception timeframes. 1

Mechanism and Monitoring

How It Works

  • Clomiphene blocks hypothalamic estrogen receptors, neutralizing negative feedback and enhancing LH-RH, FSH-RH, and gonadotropin secretion 2
  • Increased LH stimulates Leydig cells to produce testosterone, which maintains the tubular environment necessary for spermatogenesis 2
  • FSH, LH, and testosterone levels all increase significantly during treatment 6, 3, 4

Monitoring Parameters

  • Baseline: FSH, LH, testosterone, prolactin, estradiol, and semen analysis 3
  • After 3-4 months: Repeat hormone panel and semen analysis 3
  • Follow-up semen analysis 6-8 weeks post-treatment 3

Important Caveats

What Does NOT Improve

  • Sperm morphology typically remains unchanged with clomiphene therapy 2, 3
  • Semen volume is not affected 5

Long-Term Considerations

  • The marked elevation in testosterone levels may theoretically affect androgen-dependent organs like the prostate later in life, though clinical significance is uncertain 4
  • No negative side effects were reported in the studies reviewed 3

Alternative Approaches

  • For men with hypogonadotropic hypogonadism, hCG 500-2,500 IU administered 2-3 times weekly is the preferred initial therapy 8
  • Aromatase inhibitors and hCG can be used off-label in non-obstructive azoospermia to potentially improve sperm retrieval rates, though evidence is limited 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Effect of clomiphene citrate on sperm density in male partners of infertile couples.

Indian journal of physiology and pharmacology, 2007

Research

[Clomiphene citrate therapy in idiopathic male infertility].

Hinyokika kiyo. Acta urologica Japonica, 1988

Guideline

Clomiphene Citrate Dosing for Female Infertility

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

HCG Dosing and Benefits in Assisted Reproductive Technology and Male Hypogonadotropic Hypogonadism

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Related Questions

What is the recommended dosing of clomiphene (clomifene citrate) for men seeking to preserve sperm virility?
What is the recommended dose of Clomid (clomiphene citrate) for sperm preservation in men?
Does clomiphene citrate reduce negative feedback on pituitary gonadotropin release, resulting in an increase in Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH) and testosterone (T) levels?
What is the recommended dosing of Clomid (clomiphene citrate) for a male patient with infertility?
What is the recommended regimen for stimulating spermatogenesis with Clomiphene citrate?
What is the appropriate initial management for an adult with hypertension who experiences burning low‑back pain each morning on arising?
What are the absolute and relative contraindications to intravenous alteplase (tPA) for acute ischemic stroke?
What are the causes of cardiogenic shock?
What are the available pharmacologic drugs and combinations for the treatment of chronic obstructive pulmonary disease (COPD)?
What are the recommended initial and maintenance doses of methimazole for treating hyperthyroidism (Graves disease) in adults, and how should the dose be adjusted for severe disease, elderly patients, hepatic impairment, renal impairment, children, and during the first trimester of pregnancy?
In a patient on warfarin with an INR of 1.5 who meets all other eligibility criteria for intravenous alteplase (symptom onset ≤4.5 hours, no intracranial hemorrhage, blood pressure <185/110 mm Hg, platelet count ≥100 000/µL, no recent major surgery or trauma), should thrombolysis be administered?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.